Eli Lilly stock lower after China approves orforglipron pill

China approved Eli Lilly's oral weight-loss medicine orforglipron on Thursday, November 12, 2026, according to Reuters. The Chinese medicines regulator cleared the pill, giving Lilly a regulatory foothold for an oral obesity treatment in one of the largest potential markets worldwide.

Eli Lilly stock traded at 1,292.50 euros on Lang & Schwarz at 1:39 p.m. CET on Friday, November 13, 2026, 1.34 percent below the Xetra close of Thursday, November 12, at 1,310.00 euros. The euro quotation reflects the German listing, while Lilly's primary market is in the United States.

China expands the obesity opportunity

Orforglipron is designed as an oral alternative to injectable weight-loss medicines. The Chinese approval could broaden Lilly's commercial reach beyond its established cardiometabolic franchise, although the regulatory decision alone does not establish the timing or scale of the launch.

For investors, the next practical questions are pricing, reimbursement and distribution. Lilly must also build supply and convert regulatory access into prescriptions in a market where competition from other obesity-drug developers is likely to remain intense. The approval therefore adds a market opportunity, but commercial execution will determine its financial contribution.

The S&P 500 remains the relevant broad-market reference for the U.S.-listed pharmaceutical group.

More news and analyses on Eli Lilly stock.